Research from Rutgers Cancer Institute of New Jersey ( Unined States ) has shown improved overall survival at five years for pediatric patients with early-stage Hodgkin lymphoma when treated with chemotherapy followed by radiotherapy versus chemotherapy alone.
The work is believed to be the largest retrospective study to date involving this population.
There is no well-defined standard of care for pediatric patients with early-stage Hodgkin lymphoma. Current treatments include chemotherapy alone or chemotherapy followed by radiotherapy, known as combined modality therapy. This latter form of treatment is found to be manageable for this population but can result in toxic side effects.
While both chemotherapy and radiotherapy alone are associated with increased risk of toxic effects, there has been an emphasis on reducing the number of chemotherapy cycles and potentially the need for radiotherapy for these patients. This use is decreasing, but the strategy remains controversial.
In United States there has been a notable decrease in combined modality therapy, especially in clinical trials, many of which are designed to avoid this strategy.
This form of treatment has shown to be effective with event-free survival rates greater than 80% and overall survival rates greater than 95%.
The question then becomes: does treatment benefit outweigh the risk of long-term side effects ?
Investigators explored the use of combined modality therapy and its association with survival in this subset of patients.
Using data from the National Cancer Database, 5,657 pediatric patients ( mean age 17.1 ) with stage 1 or stage 2 classic Hodgkin lymphoma were analyzed in this study.
Most patients were white ( 82.9% ) and female ( 53% ). Male patients ( 48.1% ) were more likely to receive combined modality therapy than female patients ( 43.6% ).
A little more than half of patients ( 50.3% ) received radiotherapy following chemotherapy.
The most common radiotherapy was photon therapy ( 59% ).
Median follow-up for the analyzed cohort was 5.1 years.
Analysis showed combined modality therapy was associated with improved overall survival at five years ( 97.3% ), as compared to those who received chemotherapy alone ( 94.5% ).
The study also found that use of combined modality therapy was preferential in younger patients, male patients, those with stage 2 disease, and those with favorable insurance.
Adolescent and young adult patients had the most impressive benefit with combined modality therapy versus chemotherapy alone.
Conversely, the youngest patients ( aged one to 13 years ) appeared to benefit the least from this combined form of treatment.
There were study limitations including the inability to control for unreported prognostic factors, such as presence of systemic symptoms, number of nodal sites and bulk of disease, because the data set lacked this information.
The limited follow-up of the study ( median, 5.1 years ) likely has not captured secondary late effects associated with combined modality therapy and its potential effect on survival. ( Xagena )
Source: Rutgers Cancer Institute of New Jersey, 2019